» Articles » PMID: 23271325

Novel Insights into Depression and Antidepressants: a Synergy Between Synaptogenesis and Neurogenesis?

Overview
Publisher Springer
Specialty Psychology
Date 2012 Dec 29
PMID 23271325
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Major depressive disorder has been associated with manifold pathophysiological changes. These include metabolic abnormalities in discreet brain areas; modifications in the level of stress hormones, neurotransmitters, and neurotrophic factors; impaired spinogenesis and synaptogenesis in crucial brain areas, such as the prefrontal cortex and the hippocampus; and impaired neurogenesis in the hippocampus. Antidepressant therapy facilitates remission by reversing most of these disturbances, indicating that these dysfunctions may participate causally in depressive symptomatology. However, few attempts have been made to integrate these different pathophysiologies into one model. The present chapter endeavors (1) to review the extant literature in the field, with particular focus on the role of neurogenesis and synaptogenesis in depression; (2) and to suggest a possible interplay between these two processes, as well as, describe the ways by which improving both neurogenesis and synaptogenesis may enable effective recovery by acting on a larger neuronal network.

Citing Articles

Repeated lysergic acid diethylamide (LSD) reverses stress-induced anxiety-like behavior, cortical synaptogenesis deficits and serotonergic neurotransmission decline.

De Gregorio D, Inserra A, Enns J, Markopoulos A, Pileggi M, El Rahimy Y Neuropsychopharmacology. 2022; 47(6):1188-1198.

PMID: 35301424 PMC: 9018770. DOI: 10.1038/s41386-022-01301-9.


Antidepressant activity of pharmacological and genetic deactivation of the small-conductance calcium-activated potassium channel subtype-3.

Nashed M, Waye S, Hasan S, Nguyen D, Wiseman M, Zhang J Psychopharmacology (Berl). 2022; 239(1):253-266.

PMID: 34982171 DOI: 10.1007/s00213-021-06045-w.


Abnormal expression profile of plasma-derived exosomal microRNAs in patients with treatment-resistant depression.

Li L, Naveed M, Du Z, Ding H, Gu K, Wei L Hum Genomics. 2021; 15(1):55.

PMID: 34419170 PMC: 8379796. DOI: 10.1186/s40246-021-00354-z.


Elucidating the Possible Role of FoxO in Depression.

Rana T, Behl T, Sehgal A, Mehta V, Singh S, Sharma N Neurochem Res. 2021; 46(11):2761-2775.

PMID: 34075521 DOI: 10.1007/s11064-021-03364-4.


Research on the Development of Theme Trends and Changes of Knowledge Structures of Drug Therapy Studies on Major Depressive Disorder Since the 21 Century: A Bibliometric Analysis.

Duan L, Gao Y, Shao X, Tian C, Fu C, Zhu G Front Psychiatry. 2020; 11:647.

PMID: 32754061 PMC: 7367417. DOI: 10.3389/fpsyt.2020.00647.